DISCLOSURE STATEMENT

Form PTO-1449 (Modified)

FEB 1 5 2002

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 27373/36638A Serial No.

09/964,042

Applicant

Weichselbaum, R. et al.

Filing Date

1633

(Use several sheets if necessary)

September 26, 2001

RECEIVED

			U.S. PA	TENT DOCUMEN	YIS FEB	2 7 2002	
*Examiner Initials		Document Number	Issue Date	Name	TEÇH		Filing Date Of If Appropriate
	A1	4,769,331	09/06/88	Roizman et al.	435	69.1	
	A2	4,859,587	08/22/89	Roizman	435	68	
,	A3	4,999,296	03/21/91	Kit et al.	435	69.1	
	A4	5,068,192	11/26/91	Cochran	435	235.1	
	A5	5,288,641	02/22/94	Roizman	435	320.1	
	A6	5,328,688	07/12/94	Roizman	424	205.1	
	A7	5,360,893	11/94	Owens et al.	530	350	
M	A8	5,585,096	12/17/96	Martuza et al.	424	93.2	
NEXT	A9	5,593,879	01/97	Stellar et al.	435	240.1	

FOREIGN PATENT DOCUMENTS								
							Translation	
*Examiner		Document Number	Publication Date	Country	Class	Subclass	Yes	No
	B1	EP 453242	10/23/91	EPO				
Ø	B2	EP 243155	10/28/87	ЕРО				
	В3	WO 92/04050	03/19/92	PCT				
6000/	B4	WO 96/00007	01/04/96	PCT				
	B5	WO 97/26904	07/31/97	PCT				

EXAMINER 2

DATE CONSIDERED

(U- 6- 07-

FEB 1 5 2002

INFORMATION DISCLOSION

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 27373/36638A

Serial No. -09/964,042

Applicant

Weichselbaum, R. et al.

FEB 2 7 2002

Filing Date

September 26, 2001

162NTER 1600/200

#### INFORMATION DISCE OSURE STATEMENT

(Use several sheets if necessary)

			OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	7	C1	Aas et al., "Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients," Nature Medicine, 2(7): 811-814 (1996).
		C2	Ackermann <i>et al.</i> , "Identification by Antibody to a Synthetic Peptide of a Protein Specified by a Diploid Gene Located in the Terminal Repeats of the L Component of Herpes Simplex Virus Genome", <i>J. Virol.</i> , 58(3):843-850 (1986).
,		СЗ	Ackermann <i>et al.</i> , "Characterization of Herpes Simplex Virus 1 α Proteins 0, 4, and 27 with Monoclonal Antibodies," <i>J. Virology</i> , 52(1):108-118 (1984).
		C4	Advani, S.J. <i>et al.</i> "Enhancement of Replication of Genetically Engineered Herpes Simplex Viruses by Ionizing Radiation: A New Paradigm for Destruction of Therapeutically Intractable Tumors," <i>Gene Therapy</i> , 5:160-165 (1998).
	•	C5	Andreansky et al., "Evaluation of Genetically Engineered Herpes Simplex Viruses as Oncolytic Agents for Human Malignant Brain Tumors," Cancer Research, 57:1502-1509 (1997).
	٠	C6	Andreansky <i>et al.</i> , "Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins," <i>Gene Therapy</i> , 5(1):121-130 (1998).
		C7	Barinaga, M., "Cell Suicide: By ICE, Not Fire", Science, 263:754-756 (1994).
		C8	Batistatou, A. et al., "Aurintricarboxylic Acid Rescues PC12 Cells and Sympathetic Neurons from Cell Death Caused by Nerve Growth Factor Deprivation: Correlation with Suppression of Endonuclease Activity", J. Cell Biol., 115(2):461-471 (1991).
		С9	Bischoff, J.R. et al., "An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells," <i>Science</i> , 274: 373-376 (October, 1996).
8		C10	Braun et al., "Application of Denatured, Electrophoretically Separated, and Immobilized Lysates of Herpes Simplex Virus-Infected Cells for Detection of Monoclonal Antibodies and for Studies of the Properties of Viral Proteins," J. Virol., 46:103-112 (1983).

EXAMINER	DATE CONSIDERED
<del></del>	1836,87

<sup>\*</sup>EXAMIDER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 3 Form PTO-1449 (Modified) Atty. Docket No. Serial No. U.S. Department of Commerce Patent and Trademark Office FEB 1 5 2002 27373/36638A 09/964,042 Applicant Weichselbaum, R. et al. Filing Date Group September 26, 2001 1633 (Use several sheets if necessary

FFR 2 7 2002

·		TECH CENTER 1600/2900
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
a	) C11	Brown <i>et al.</i> , "Genetic Studies with Herpes Simplex Virus Type 1. The Isolation of Temperature-sensitive Mutants, their Arrangement into Complementation Groups and Recombination Analysis Leading to a Linkage Map," <i>J. Gen. Virol.</i> , 18:329-346 (1973).
	C12	Brown, D. "Gene Therapy 'Oversold' By Researchers, Journalists", <i>The Washington Post</i> , A22, Friday, December 8, 1995
	C13	Centifanto-Fitzgerald <i>et al.</i> , "Ocular Disease Pattern Induced By Herpes Simplex Virus is Genetically Determined By A Specific Region of Viral DNA", <i>J. Exp. Med.</i> , 155:475-489 (1982).
	C14	Chambers et al., "Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma", Proc. Natl. Acad. Sci., USA, 92:1411-1415 (1995).
-	C15	Chou and Roizman, "Herpes Simplex Virus 1 (HSV-1) Gene γ <sub>1</sub> 34.5 Blocks the Neuroblastoma Cells from Cell Death (Apoptosis) Induced by Viral Infection," <i>J. Cell. Biochem.</i> , Keystone Symposia, Supplement 10C, February 21-March 7, 1992, Abstract N303, p. 136.
in cells exhibiting enhanced phosphorylation of translation initiation factor eIF and premature shutoff of protein synthesis after infection with γ <sub>1</sub> 34.5 mutants		Chou et al., "Association of a $M_r$ 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 $\alpha$ and premature shutoff of protein synthesis after infection with $\gamma_1$ 34.5 mutants of herpes simplex virus 1," <i>Proc. Natl. Acad. Sci. (USA)</i> 92:10516-10520 (1995).
the cis-Acting and Recombination Sites within the Domain of the a Sequence		Chou et al., "Isomerization of Herpes Simplex Virus 1 Genome: Identification of the cis-Acting and Recombination Sites within the Domain of the a Sequence", Cell, 41:803-811 (1985).
	C18	Chou <i>et al.</i> , "The γ <sub>1</sub> 34.5 gene of herpes simplex virus 1 precludes neuroblastoma cells form triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells," <i>Proc. Natl. Acad. Sci. (USA)</i> 89:3266-3270 (1992).
9	C19	Chou et al., "The Herpes Simplex Virus 1 Gene for ICP34.5, Which Maps in Inverted Repeats, Is Conserved in Several Limited-Passage Isolates but Not in Strain 17syn+", J. Virol., 64(3):1014-1020 (1990).

EXAMINER	DATE CONSIDERED
*EXAMINED: Initial if reference considered, whether or not cita	tion is in conformance with MDED 600. Draw line through

Form PTO-1449 (Modified) **ÖSURE STATEMENT** 

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 27373/36638A Serial No. 09/964,042

Applicant

Weichselbaum, R. et al.

September 26, 2001


Group 1633

FEB 2 7 2002

	OTHER DECOMENTER (1600/2000 uthor, Title, Date, Pertinent Pages, etc.)				
<	7	C20	Chou et al., "The Terminal α Sequence of the Herpes Simplex Virus Genome Contains the Promoter of a Gene Located in the Repeat Sequences of the L Component", J. Virol., 57(2):629-637 (1986).		
6		C21	Chou, J. <i>et al.</i> , "Mapping of Herpes Simplex Virus-1 Neurovirulence to γ <sub>1</sub> 34.5, a Gene Nonessential for Growth in Culture," <i>Science</i> , 250:1262-1266 (November, 1990).		
		C22	Clem et al., "Prevention of Apoptosis by a Baculovirus Gene During Infection of Insect Cells," Science, 254:1388-1399 (1991).		
		C23	Coghlan, A., "Gene dream fades away", <i>New Scientist</i> , pp. 14-15 (November, 1995).		
		C24	Corey et al., "Infections with Herpes Simplex Viruses," New England J. Medicine, 314:686-691 (1986).		
	-	C25	Culver, K.W. et al., "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors," Science, 256:1550-1552 (June, 1992).		
		C26	Datta et al., "Overexpression of Bcl-x <sub>L</sub> by Cytotoxic Drug Exposure Confers Resistance to Ionizing Radiation-induced Internucleosomal DNA Fragmentation," Cell Growth & Differentiation, 6:363-370 (April, 1995).		
		C27	Davidson <i>et al.</i> , "Location and Orientation of Homologous Sequences in the Genomes of Five Herpes Viruses," <i>J. Gen. Virol.</i> , <i>64</i> :1972-1942 (1983).		
		C28	Deiss et al., "Functional Domains within the a Sequence Involved in the Cleavage-Packaging of Herpes Simplex Virus DNA", J. Virol., 59:605-618 (1986).		
		-C29-	-DeLuca-et-al., "Isolation and Characterization of Deletion Mutants of Herpes Simplex Virus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4," J. Virology, 56(2):558-570 (1985).		
		C30	Dolan et al., "Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17," Journal General Virology, 73(4):971-973 (1992).		

EXAMINER	7 -	$\bigcirc$	
		/-	

DATE CONSIDERED



,		FEB 2 7 2007
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
91	C31	Ejercito et al., "Characterization of Herpes Simplex Virus Strains Differing in their Effects on Social Behaviour of Infected Cells", J. Gen. Virol., 2:357-364 (1968).
	C32	Field <i>et al.</i> , "The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice", <i>J. Hyg., Camb.</i> , 81:267-277 (1978).
	C33	Gagliardini et al., "Prevention of Vertebrate Neuronal Death by the crmA Gene", Science, 263:826-828 (1994).
	C34	Gregory et al., "Activation of Epstein-Barr Virus Latent Genes Protects Human B Cells From Death by Apoptosis," <i>Nature</i> , 349:612-614 (1991).
	C35	Hallahan, et al. "Spatial and temporal control of gene therapy using ionizing radiation," <i>Nature Medicine</i> , 1(8):786-791 (1995).
	C36	Hammer et al., "Temporal Cluster of Herpes Simplex Encephalitis: Investigation by Restriction Endonuclease Cleavage of Viral DNA", J. Infectious Diseases, 141(4):436-440 (1980).
	C37	Hayward <i>et al.</i> , "Anatomy of herpes simplex virus DNA: Evidence for four populations of molecules that differ in the relative orientations of their long and short components", <i>Proc. Natl. Acad. Sci.</i> , USA, 72(11):4243-4247 (1975).
	C38	Heise <i>et al.</i> , "ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents," <i>Nature Medicine</i> , 3(6):639-645 (1997).
	C39	Henderson, S., "Induction of <i>blc</i> -2 Expression by Epstein Barr Virus Latent Membrane Protein 1 Protects Infected B Cells from Programmed Cell Death," <i>Cell</i> , 65:1107-1115 (1991).
	C40	Hollstein, M. et al., "p53 Mutations in Human Cancers," Science, 253: 49-53 (July, 1991).
9	C41	Honess et al., "Proteins Specified by Herpes Simplex Virus XI. Identification and Relative Molar Rates of Synthesis of Structural and Nonstructural Herpes Virus Polypeptides in the Infected Cell", J. Virol., 12:1347-1365 (1973).

EXAMINER	50	DATE CONSIDERED
<del></del>		

Form PTO-1449 (Modified) U.S. Department of Commerce PFEBd 2ra7m2002rice

Atty. Docket No. 27373/36638A Serial No. 09/964,042

SHEET 6 of 12

Applicant

Weichselbaum, R. et al.

September 26, 2001

Group 1633

(Use several sheets if necessary)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
C42	Houldsworth <i>et al.</i> , "Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation," <i>Oncogene</i> , 16:2345-2349 (1998).				
C43	Hubenthal-Voss <i>et al.</i> , "Mapping of Functional and Antigenic Domains of the α4 Protein of Herpes Simplex Virus 1", <i>J. Virol.</i> , 62:454-462 (1988).				
. C44	Itoh et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," Cell, 66:233-243 (1991).				
C45	Javier <i>et al.</i> , "Genetic and Biological Analyses of a Herpes Simplex Virus Intertypic Recombinant Reduced Specifically for Neurovirulence", <i>J. Virol.</i> , 61(6):1978-1984 (1987).				
C46	Johnson et al., "Why Do Neurons Die When Deprived of Trophic Factor?" Neurobiology of Aging, 10:549-552 (1989).				
. C47	Katz et al., "Quantitative Polymerase Chain Reaction Analysis of Herpes Simplex Virus DNA in Ganglia of Mice Infected with Replication-Incompetent Mutants," J. Virology, 64(9):4288-4295 (1990).				
C48	Kauffman et al., "Pathogenesis of Viral Infections," in Fundamental Virology, Fields et al. (Eds.), Chapter 10, Raven Press, New York, pp.153-167 (1986).				
C49	Kehm et al., "Restitution of the UL56 gene expression of HSV-1 HFEM led to restoration of virulent phenotype; deletion of the amino acids 217 to 234 of the UL56 protein abrogates the virulent phenotype," Virus Research, 40:17-40 (1996).				
C50	Kieff et al., "Size, Composition, and Structure of the Deoxyribonucleic Acid of Herpes Simplex Virus Subtypes 1 and 2", J. Virol., 8:125-132 (1971).				
C51	Kyte et al., "A Simple Method for Displaying the Hydropathic Character of a Protein," J. Mol. Biol., 157:105-132 (1982).				
C52	Larder-et-al., "Restoration-of-Wild-type-Pathogenicity to an Attenuated DNA Polymerase Mutant of Herpes Simplex Virus Type 1", J. Gen. Virol., 67:2501-2506 (1986).				

EXAMINER	$\leq 0$	

DATE CONSIDERED

Form PTO-1449 (Modified) Fair 1 5 2062

# RECURING Commerce Patent and Trademark Office

Atty. Docket No. 27373/36638A

Serial No. 09/964,042

FEB 2 7 2002

Applicant Weichselbaum, R. et al.

September 26, 2001

Filing Date

Group 1633

#### INFORMATION BESCLOSTERE STAFFERMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) C53 Linnemann et al., "Transmission of Herpes-Simplex Virus Type 1 in a Nursery for The Newborn Identification of Viral Isolates By D.N.A. "Fingerprinting", Lancet, 1:964-966 (1978). C54 Loo et al., "Serial Passage of Embryonic Human Astrocytes in Serum-Free, Hormone-Supplemented Medium," J. Neuroscience Research, 28:101-109 (1991).C55 Lord et al., "Sequence of MyD116 cDNA: A novel myeloid differentiation primary response gene induced by IL6," Nucleic Acid Research, 18(9):2823 (1990).C56 Lowe, S.W. et al., "p53 Status and the Efficiency of Cancer Therapy in Vivo," Science, 266:807-810 (November, 1994). Mackem et al., "Structural Features of the Herpes Simplex Virus α Gene 4, 0, C57 and 27 Promoter-Regulatory Sequences Which Confer α Regulation on Chimeric Thymidine Kinase Genes," J. Virology, 44(3):939-949 (1982). C58 Maclean et al., "Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17<sup>+</sup> between immediate early gene 1 and the 'a' sequence", Journal of General Virology, 72(3):631-639 (1991). MacLean et al., "The R<sub>1</sub> neurovirulence locus in herpes simplex virus type 2 C59 strain HG52 plays no role in latency", J. Gen. Virol., 72:2305-2310 (1991). Martuza, R.L. et al., "Experimental Therapy of Human Glioma by Means of a C60 Genetically Engineered Virus Mutant," Science, 252:854-856 (May, 1991). C61 McGeoch et al., "Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1", Nucleic Acids Research, 14:1727-1745 (-1.986)-C62 McGeoch et al., "The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1", J. Gen. Virol., 64:1531-1574 (1988).

EXAMINER	DATE	CONSIDERED
AUI	,	18/6/02

L'ÓSURE STATEMENT

SHEET 8 of 12

Form PTO-1449 (Modified)

U.S. Behartment of Commerce Patent and Trademark Office TECH CENTER 1600/2900

Atty. Docket No. 27373/36638A

Serial No. 09/964,042

Applicant

Weichselbaum, R. et al.

September 26, 2001

Filing Date

Group 1633

(Use several sheets if necessary)

INFORMATIC

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) McGoech et al., "Comparative sequence analysis of the long repeat regions and C63 adjoining parts of the long unique regions in the genomes of herpes simplex viruses types 1 and 2", J. Gen. Virol., 72:3057-3075 (1991). C64 Meignier et al., "Construction and In Vivo Evaluation of Two Genetically Engineered Prototypes of Live Attenuated Herpes Simplex Virus Vaccines", Vaccines, 87, Cold Spring Harbor Laboratory, pp. 368-373 (1987). C65 Meignier et al., "In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020. II. Studies in Immunocompetent and Immunosuppressed Owl Monkeys (Aotus trivirgatus)," J. Infectious Diseases, 162:313-321 (1990). Meignier et al., "In Vivo Behavior of Genetically Engineered Herpes Simplex C66 Viruses R7017 and R7020: Construction and Evaluation in Rodents", J. Infectious Diseases, 158: 602-614 (1988). Meignier et al., "Virulence of and Establishment of Latency by Genetically C67 Engineered Deletion Mutants of Herpes Simplex Virus 1", Virology, 162:251-254 (1988).Mineta et al., "Treatment of Malignant Gliomas Using Ganciclovir-hypersensitive, C68 Ribonucleotide Reductase-deficient Herpes Simplex Viral Mutant," Cancer Research, 54: 3963-3966 (1994). C69 Mocarski et al., "Site-specific inversion sequence of the herpes simplex virus genome: Domain and structural features", Proc. Natl. Acad. Sci., USA, 78:7047-7051 (1981). Mocarski et al., "Structure and Role of the Herpes Simplex Virus DNA Termini C70 in Inversion, Circularization and Generation of Virion DNA", Cell, 31:89-97 (1982).Moriuchi et al., "Enhanced Tumor Cell Killing in the Presence of Ganciclovir by C71 Herpes Simplex Virus Type 1 Vector-directed Coexpression of Human Tumor

	EXAMINER	DATE CONS	IDERED
--	----------	-----------	--------

Research, 58:5731-5737 (1998).

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Necrosis Factor-α and Herpes Simplex Virus Thymidine Kinase," Cancer

SHEET 9 of 12

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S.F.B. u. 71 2002 FCH CENTER 1600/290 Aug. Docket No. 27373/36638A

O9/964,042

Weichselbaum, R. et al.

Filing Date September 26, 2001 1633

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C72	Morris Academic Press Dictionary of Science technology Academic Press Harcourt Brace Jovanich Publishers, pp. 917 and 2276 (1992).
	C73	Morse et al., "Anatomy of Herpes Simplex Virus (HSV) DNA", J. Virol., 26(2):389-410 (1978).
	C74	Mulligan, R.C., "The Basic Science of Gene Therapy", Science, 260:926-930 (May, 1993).
	C75	Nagata et al., "The Fas Death Factor," Science, 267:1449-1456 (1995).
·	C76	Orkin et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy" (December, 1995).
-7	C77	Peppel et al., "A Simple and Fast Method to Extract RNA from Tissue Culture Cells," BioTechniques, 9(6):711-712 (1990).
·	C78	Perry et al., "Characterization of the IE110 Gene of Herpes Simplex Virus Type 1", J. Gen. Virol., 67:2365-2380 (1986).
	C79	Perry et al., "The DNA Sequences of the Long Repeat Region and Adjoining Parts of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1," J. Gen. Virol., 69:2831-2846 (1988).
	C80	Poffenberger et al., "A Noninverting Genome of a Viable Herpes Simplex Virus 1: Presence of Head-to-Tail Linkages in Packaged Genomes and Requirements for Circularization After Infection", J. Virol., 53(2):587-595 (1985).
	C81	Poffenberger et al., "Characterization of a viable, noninverting herpes simplex virus 1 genome derived by insertion and deletion of sequences at the junction of components L and S", Proc. Natl. Acad. Sci., USA, 80:2690-2694 (1983).
	C82	Post et al., "A Generalized Technique for Deletion of Specific Genes in Large Genomes: α-Gene-22-of-Herpes-simplex-Virus-1-is-Not-Essential-for-Growth", Cell, 25:227-232 (1981).
9	C83	Post <i>et al.</i> , "Cloning of reiterated and nonreiterated herpes simplex virus 1 sequences as <i>Bam</i> HI fragments", <i>Proc. Natl. Acad. Sci.</i> , <i>USA</i> , <i>77</i> (7):4201-4205 (1980).

EXAMINER /		DATE CONSIDERED
<del></del>	· ·	C



SHEET \_10\_ of \_12

Form PTO-1449 (Modified) FEB 1 5 2002

Patent and Trademark Office

Atty. Docket No. 27373/36638A Serial No. 09/964,042

TECH CENTER 1600/2900 Applicant

Weichselbaum, R. et al. CLOSURE STATEMENT

Group

(Use several sheets if necessary)

September 26, 2001 1633

			OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
		C84	Ram <i>et al.</i> , "Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells," <i>Nature Medicine</i> , 3(12):1354-1361 (1997).
		C85	Rawson et al., "Death of Serum-free Mouse Embryo Cells Caused by Epidermal Growth Factor Deprivation," J. Cell Biology, 113:671-679 (1991).
+.		C86	Renfranz et al., "Region-Specific Differentiation of the Hippocampal Stem Cell Line HiB5 upon implantation into the Developing Mammalian Brain," Cell, 66:713-729 (1991).
		C87	Roizman, B., in Virology, Second Edition, Field et al. (Eds.) Chapter 64, Raven Press Ltd., New York (1990).
	•	C88	Roizman, B., in Fundamental Virology, Second Edition, Field et al. (Eds.) Chapters 5 and 33-34, Raven Press Ltd., New York (1991).
		C89	Roizman et al., "The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors," <i>Proc Natl. Acad. Sci. (USA)</i> 93:11307-11312 (1996).
		C90	Roller <i>et al.</i> , "Herpes Simplex Virus 1 RNA-Binding Protein U <sub>s</sub> 11 Negatively Regulates the Accumulation of a Truncated Viral mRNA," <i>J. Virology</i> , 65(11):5873-5879 (1991).
		C91	Ryder <i>et al.</i> , "Establishment and Characterization of Multipotent Neural Cell Lines Using Retrovirus Vector-Mediated Oncogene Transfer", <i>J. Neurobiol.</i> , 21:356-375 (1990).
		C92	Sanger et al., "DNA sequencing with chain-terminating inhibitors", Proc. Natl. Acad. Sci., USA, 74:5463-5467 (1977).
		C93	Sentman <i>et al.</i> , "bcl-2 Inhibits Multiple Forms of Apoptosis but Not Negative Selection in Thymocytes," <i>Cell</i> , 67:879-888 (1991).
		-C94	-Sheldrick-et-al., "Inverted-Repetitions-in-the-Chromosome-of-Herpes-Simplex Virus", Cold Spring Harbor Symp. Quant. Biol., 39:667-678 (1975).
5		C95	Shih <i>et al.</i> , "Expression of hepatitis B virus S gene by herpes simplex virus type 1 vectors carrying α- and β-regulated gene chimeras," <i>Proc. Natl. Acad. Sci. (USA)</i> 81:5867-5870 (1984).

EXAMINER	DATE CONSIDERED
(15/5	- 18/4/00

U.S. Department of Commerce Atty. Docket No. TECH-CENTER 4600/29 027373/36638A Form PTO-1449 (Modified)

DISCLOSURE STATEMENT

SHEET 11 of <u>12</u>

Serial No. 09/964,042

Applicant

Weichselbaum, R. et al.

Filing Date

Group

(Use several sheets if necessary)


September 26, 2001 1633

			OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
2	)	C96	Snyder <i>et al.</i> , "Mulipotent Neural Cell Lines Can Engraft and Participate in Development of Mouse Cerebellum," <i>Cell</i> , 68:33-51 (1992).
		C97	Steller, H., "Mechanisms and Genes of Cellular Suicide," <i>Science</i> , 267:1445-1449 (1995).
		C98	Stevens et al., "Restriction of Herpes Simplex Virus By Macrophages", J. Exp. Medicine, 133:19-38 (1971).
		C99	Strasser et al., "bcl-2 Transgene Inhibits T Cell Death and Perturbs Thymic Self-Censorship," Cell, 67:889-899 (1991).
		C100	Taha et al., "A Variant of Herpes Simplex Virus Type 2 Strain HG52 with a 1.5 kb Deletion in R <sub>L</sub> between 0 to 0.02 and 0.81 to 0.83 Map Units Is Nonneurovirulent for Mice", J. Gen. Virol., 70:705-716 (1989).
	<del></del>	C101	Taha et al., "The Herpes Simplex Virus Type 2 (HG52) Variant JH2604 Has a 1488 bp Deletion which Eliminates Neurovirulence in Mice", Journal of General Virology, 70(11):3073-3078 (1989).
		C102	Thompson <i>et al.</i> , "Biological Characterization of a Herpes Simplex Virus Intertypic Recombinant Which Is Completely and Specifically Non-Neurovirulent", <i>Virology</i> , 131:171-179 (1983).
		C103	Thompson <i>et al.</i> , "Physical Location of a Herpes Simplex Virus Type-1 Gene Function(s) Specifically Associated with a 10 Million-Fold Increase in HSV Neurovirulence", <i>Virology</i> , <i>131</i> :180-192 (1983).
		C104	Thompson <i>et al.</i> , "Rescue of a Herpes Simplex Virus Type 1 Neurovirulence Function with a Cloned DNA Fragment", <i>J. Virology</i> , 35(2):504-508 (1985).
		C105	Thompson et al., "Vaccine potential of a live avirulent herpes simplex virus," Microbial Pathogenesis, 1:409-416 (August, 1986).
9		C106	Thompson <i>et al.</i> , "Functional and Molecular Analyses of the Avirulent Wild-Type Herpes Simplex Virus Type 1 Strain KOS, <i>J. Virology</i> , 58(1):203-211 (1986).
y	<i>/</i> —	C106	Type Herpes Simplex Virus Type 1 Strain KOS, J. Virology, 58(1):203-211

EXAMINER DATE CONSIDERED



SHEET <u>12</u> of <u>12</u>



TECH CENTER 4600/2900

Atty. Docket No. 27373/36638A Serial No.

09/964,042

#### INFORMATION DISCLOSURE STATEMENT

Weichselbaum, R. et al.

Applicant

Group

(Use several sheets if necessary)

Filing Date September 26, 2001 1633

			OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
A	)	C107	Thompson <i>et al.</i> , "Herpes Simplex Virus Neurovirulence and Productive Infection of Neural Cells Is Associated with a Function Which Maps between 0.82 and 0.832 Map Units on the HSV Genome," <i>Virology</i> , 172(2):435-450 (1989).
<u> </u>		C108	Varmuza et al., "Signals for Site-Specific Cleavage of HSV DNA: Maturation Involves Two Separate Cleavage Events at Sites Distal to the Recognition Sequences", Cell, 41:793-802 (1985).
		C109	Vlazny <i>et al.</i> , "Site-specific cleavage/packaging of herpes simplex virus DNA and the selective maturation of nucleocapsids containing full-length viral DNA", <i>Proc. Natl. Acad. Sci.</i> , <i>USA</i> , 79:1423-1427 (1982).
		C110	Wadsworth et al., "Anatomy of Herpes Simplex Virus DNA", J. Virol., 15(6):1487-1497 (1975).
٠		C111	Warren et al., "Isolation of Latent Herpes Simplex Virus from the Superior Cervical and Vagus Ganglions of Human Beings," New England Journal Medicine, 298:1068-1070 (1978).
		C112	Whitley, R.J. <i>et al.</i> , "Replication, Establishment of Latency, and Induced Reactivation of Herpes Simplex Virus γ <sub>1</sub> 34.5 Deletion Mutants in Rodent Models," <i>J. Clin. Invest.</i> , 91:2387-2843 (June, 1993).
		C113	Whitley, "Herpes Simplex Viruses", pp. 1843-1887 in Virology, Second Ed., Chapter 66 Fields et al., (eds.), Raven Press, New York (1990).
<b>"</b>	_	C114	Williams, G.T., "Programmed Cell Death: Apoptosis and Oncogenesis," <i>Cell</i> , 65:1097-1098 (June, 1991).
		C115	Advani, et al., "Replication-competent, Nonneuroinvasive Genetically Engineered Herpes Virus Is Highly Effective in the Treatment of Therapy-resistant Experimental Human Tumors <sup>1</sup> ," Cancer Research 59:2055-2058 (1999)
9	A	C116	Carpenter, et al., "Sequences of the bovine herpesvirus 1 homologue of herpes simplex virus type-1 α-trans-inducing factor (UL48)," GENE 119:259-263 (1992)
		C117	Biosis Accession No. XP002141884

EXAMINER
----------

DATE CONSIDERED